2022-05-02 | NDAQ:STOK | Press Release | Stoke Therapeutics Inc. - Stockhouse

(2022-05-02 | NDAQ:STOK) Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today ann… [+10562 chars]

full article...